Regulation of vascular smooth muscle relaxation by the endothelium in health and in diabetes (with a focus on endothelium-derived hyperpolarizing factor)

Neurophysiology

Volumn 35, Issue 3-4, 2003, Pages 256-261

  Tare, Marianne ^a   Coleman, H A ^a   Parkington, H C ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Diabetes mellitus; EDHF; Endothelium; Vascular smooth muscle

Indexed keywords

ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; LY 33531; NITRIC OXIDE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ARTERIOLE; BLOOD VESSEL TONE; CELL FUNCTION; CELL HETEROGENEITY; CLINICAL FEATURE; CONFERENCE PAPER; DIABETES MELLITUS; ENDOTHELIUM LESION; HUMAN; HYPERPOLARIZATION; MORBIDITY; MORTALITY; NONHUMAN; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; TISSUE PERFUSION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0442294203     PISSN: 00902977     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEPH.0000008786.79520.95     Document Type: Conference Paper

References (55)

1. R. F. Furchgott and J. V. Zawadzki, "The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine," Nature, 288, 373-376 (1980).
2. R. A. Cohen, "Dysfunction of vascular endothelium in diabetes mellitus," Circulation, 87, V67-V76 (1993).
3. L. Poston and P. D. Taylor, "Endothelium-mediated vascular function in insulin-dependent diabetes mellitus," Clin. Sci., 88, 245-255 (1995).
4. F. Cosentino and T. F. Lüscher, "Endothelial dysfunction in diabetes mellitus," J. Cardiovascul. Pharmacol., 32, Suppl. 3, S54-S61 (1998).
5. A. S. De Vriese, T. J. Verbeuren, J. Van De Voorde, et al., "Endothelial dysfunction in diabetes," Br. J. Pharmacol., 130, 963-974 (2000).
6. N. N. Chan, P. Vallance, and H. M. Colhoun, "Nitric oxide and vascular responses in Type 1 diabetes," Diabetologia, 43, 137-147 (2000).
7. G-nitro-L-arginine in rats," Am. J. Physiol., 263, H1090-H1094 (1992).
8. P. M. Zygmunt, T. Ryman, and E. D. Hogestatt, "Regional differences in endothelium-dependent relaxation in the rat: Contribution of nitric oxide and nitric oxide-independent mechanisms," Acta Physiol. Scand., 155, 257-266 (1995).
9. C. E. Hill, J. K. Phillips, and S. L. Sandow, "Heterogeneous control of blood flow amongst different vascular beds," Med. Res. Rev., 21, 1-60 (2001).
10. P. D. Taylor, J. E. Graves, and L. Poston, "Selective impairment of acetylcholine-mediated endothelium-dependent relaxation in isolated resistance arteries of the streptozotocin-induced diabetic rat," Clin. Sci., 88, 519-524 (1995).
11. S. J. Wigg, M. Tare, M. A. Tonta, et al., "Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery," Am. J. Physiol., 281, H232-H240 (2001).
12. M. Fukao, Y. Hattori, M. Kanno, et al., "Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats," Br. J. Pharmacol., 121, 1383-1391 (1997).
13. B. Nilius and G. Droogmans, "Ion channels and their functional role in vascular endothelium," Physiol. Rev., 81, 1415-1459 (2001).
14. L. Sobrevia and G. E. Mann, "Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia," Exp. Physiol., 82, 423-452 (1997).
15. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus," New Engl. J. Med., 329, 977-986 (1993).
16. United Kingdom Prospective Diabetes Study Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)," Lancet, 352, 837-853 (1998).
17. M. J. Sheetz and G. L. King, "Molecular understanding of hyperglycemia's adverse effects for diabetic complications," J. Am. Med. Assoc., 288, 2579-2588 (2002).
18. T. B. Bolton, R. J. Lang, and T. Takewaki, "Mechanisms of action of noradrenaline and carbachol on smooth muscle of guinea-pig anterior mesenteric artery," J. Physiol., 351, 549-572 (1984).
19. S. G. Taylor and A. H. Weston, "Endothelium-derived hyperpolarizing factor: A new endogenous inhibitor from the vascular endothelium," Trends Pharmacol. Sci., 9, 272-274 (1988).
20. G. Chen, H. Suzuki, and A. H. Weston, "Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels," Br. J. Pharmacol., 95, 1165-1174 (1988).
21. C. J. Garland, F. Plane, B. K. Kemp, and T. M. Cocks, "Endothelium-dependent hyperpolarization: A role in the control of vascular tone," Trends Pharmacol. Sci., 16, 23-30 (1995).
22. R. Busse, G. Edwards, M. Félétou, et al., "EDHF: Bringing the concepts together," Trends Pharmacol. Sci., 23, 374-380 (2002).
23. W. Campbell and K. Gauthier, "What is new ion endothelium-derived hyperpolarizing factors?" Curr. Opin. Nephrol. Hypertens., 11, 177-183 (2002).
24. J. McGuire, H. Ding, and C. Triggle, "Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factors," Can. J. Pharmacol., 79, 443-470 (2001).
25. T. Itoh, N. Seki, S. Suzuki, et al., "Membrane hyperpolarization inhibits agonist-induced synthesis of inositol 1,4,5-trisphosphate in rabbit mesenteric artery," J. Physiol., 451, 307-328 (1992).
26. 2+ transients in guinea-pig coronary myocytes," J. Physiol., 470, 35-44 (1993).
27. H. Tomioka, Y. Hattori, M. Fukao, et al., "Relaxation in different-sized rat blood vessels mediated by endothelium-derived hyperpolarizing factor: Importance of processes mediating pre-contractions," J. Vascul. Res., 36, 311-320 (1999).
28. J.-L. Bény, "Information networks in the arterial wall," New Physiol. Sci., 14, 68-73 (1999).
29. H. Shimokawa, H. Yasutake, K. Fujii, et al., "The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation," J. Cardiovascul. Pharmacol., 28, 703-711 (1996).
30. J. Hwa, L. Ghibaudi, P. Williams, and M. Chatterjei, "Comparison of acetylcholine-dependent relaxation in large and small arteries of rat mesenteric vascular bed," Am. J. Physiol., 266, H952-H958 (1994).
31. P. D. Taylor, A. L. McCarthey, C. R. Thomas, and L. Poston, "Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats," Br. J. Pharmacol., 107, 393-399 (1992).
32. F. Dai, A. Diederich, J. Skopec, and D. Diederich, "Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: Role of prostaglandin endoperoxides and free radicals," J. Am. Soc. Nephrol., 4, 1327-1336 (1993).
33. J. M. Lash and H. G. Bohlen, "Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles," Circ. Res., 69, 1259-1268 (1991).
34. A. S. De Vriese, J. Van De Voorde, H. J. Blom, et al., "The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate," Diabetologia, 43, 1116-1125 (2000).
35. M. A. Cotter, A. M. Jack, and N. E. Cameron, "Effects of the protein kinase Cβ inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes," Clin. Sci., 103, 311-321 (2002).
36. N. E. Cameron, S. E. M. Eaton, M. A. Cotter, and S. Tesfaye, "Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy," Diabetologia, 44, 1973-1988 (2001).
37. K. Terata, L. J. Coppey, E. P. Davidson, et al., "Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction," Br. J. Pharmacol., 128, 837-843 (1999).
38. L. J. Coppey, J. S. Gellett, and M. A. Yorek, "Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: Effect of diabetes in type 1 and type 2 diabetic rat models," Endothelium: J. Endothelial Cell Res., 10, 89-94 (2003)
39. W. A. K. Lau and J. J. Reid, "Comparison of endothelial cell function in large and small arteries from the obese zucker rats," Proc. Austral. Physiol. Pharmacol. Soc., 31, No. 2, 66P (2000).
40. D. C. Lefroy, T. Crake, N. G. Uren, et al., "Effect of inhibition of nitric oxide synthesis on epicardial coronary artery calibre and coronary blood flow in humans," Circulation, 88, 43-54 (1993).
41. J. Quilley, J. C. McGiff, P. Mieyal, et al., "NO-independent coronary vasodilation to bradykinin in diabetes," Hypertension, 28, P178 (1996).
42. A. W. Miller, P. V. G. Katakam, and M. R. Ujhelyi, "Impaired endothelium-mediated relaxation in coronary arteries from insulin-resistant rats," J. Vascul. Res., 36, 385-392 (1999).
43. + is an endothelium-derived hyperpolarizing factor in rat arteries," Nature, 396, 269-272 (1998).
44. + currents underlying the action of endothelium-derived hyperpolarizing factor in guinea-pig, rat and human blood vessels," J. Physiol., 531, 359-373 (2001).
45. H. C. Parkington, J.-A. M. Chow, R. G. Evans, et al., "Role for endothelium-derived hyperpolarizing factor in vascular tone in rat mesenteric and hindlimb circulations in vivo," J. Physiol., 542, 929-937 (2002).
46. S. L. Sandow and C. E. Hill, "Incidence of myoendothelium gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolarizing factor-mediated responses," Circ. Res., 86, 341-346 (2000).
47. S. L. Sandow, M. Tare, H. A. Coleman, et al., "Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor," Circ. Res., 90, 1108-1113 (2002).
48. A. Makino, K. Ohuchi, and K. Kamata, "Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat," Br. J. Pharmacol., 130, 549-556 (2000).
49. Ca with 1-ethyl-2-benzimidazolinone evokes smooth muscle hyperpolarization in rat isolated mesenteric artery," Br. J. Pharmacol., 134, 1548-1554 (2001).
50. T. Inoguchi, F. Ueda, F. Umeda, et al., "Inhibition of intercellular communication via gap junction in cultured aortic endothelial cells by elevated glucose and phorbol ester," Biochem. Biophys. Res. Commun., 208, 492-497 (1995).
51. T. Kuroki, T. Inoguchi, F. Umeda, et al., "High glucose induces alteration of gap junction permeability and phosphorylation of connexin-43 in cultured aortic smooth muscle cells," Diabetes, 47, 931-936 (1998).
52. H. Oku, T. Kodama, K. Sakagami, and D. G. Puro, "Diabetes-induced disruption of gap junction pathways within the retinal microvasculature," Invest. Ophthalmol. Vis. Sci., 42, 1915-1920 (2001).
53. P. R. Brink, "Gap junctions in vascular smooth muscle," Acta. Physiol. Scand., 164, 349-356 (1998).
54. T. Sato, R. Haimovici, R. Kao, et al., "Downregulation of connexin 43 expression by high glucose reduces gap junction activity in microvascular endothelial cells," Diabetes, 51, 1565-1571 (2002).
55. H. Ishii, D. Koya and G. L. King, "Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus," J. Mol. Med., 76, 21-31 (1998).